As of today (2026-06-28), the Forward Annual Dividend Yield of Ionis Pharmaceuticals is 0.00%.
As of today (2026-06-28), the Trailing Annual Dividend Yield of Ionis Pharmaceuticals is 0.00%.
LTS:0JDI's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Ionis Pharmaceuticals Forward Dividend Yield % Related Terms
LTS:0JDI vs EXEL, BBIO, AXSM: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Ionis Pharmaceuticals (LTS:0JDI) has a Forward Dividend Yield % of 0.00% as of Jun. 28, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Ionis Pharmaceuticals and its competitors. According to the industry distribution chart, Ionis Pharmaceuticals ranks #999999 out of 145 companies in the Biotechnology industry.
Is Ionis Pharmaceuticals' Forward Dividend Yield % too high?
Ionis Pharmaceuticals' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Ionis Pharmaceuticals ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ionis Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Forward Dividend Yield % compare to EXEL and BBIO?
According to the Biotechnology industry distribution chart, Ionis Pharmaceuticals ranks #999999 out of 145 companies for Forward Dividend Yield %. This places Ionis Pharmaceuticals in the lower half of its industry. The industry median Forward Dividend Yield % is 1.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.57, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Ionis Pharmaceuticals and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ionis Pharmaceuticals's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Significantly Overvalued. The stock's GF Value™ is $53.57, compared to a current price of $80.36 — trading 50% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Ionis Pharmaceuticals' overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current Forward Dividend Yield % is 0.00% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of $80.36 is trading 50% above its estimated GF Value™ of $53.57.
GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for LTS:0JDI:
Forward Dividend Yield %: 0.00%
GF Value™: $53.57 vs. price of $80.36 (50% above fair value)
No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
66GF Score
Get the complete analysis for LTS:0JDI
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDI has been successfully added to your 